Brain-derived neurotrophic factor in VMH as the causal factor for and therapeutic tool to treat visceral adiposity and hyperleptinemia in type 2 diabetic Goto–Kakizaki rats by Fumihiko Maekawa et al.
ORIGINAL RESEARCH ARTICLE
published: 02 October 2013
doi: 10.3389/fnsyn.2013.00007
Brain-derived neurotrophic factor in VMH as the causal
factor for and therapeutic tool to treat visceral adiposity
and hyperleptinemia in type 2 diabetic Goto–Kakizaki rats
Fumihiko Maekawa1,2†, Ken Fujiwara1,3†, Masako Toriya1, Yuko Maejima1, Takashi Nishio4,
Yukiyasu Toyoda5, Keiko Nohara2, Takashi Yashiro3 and Toshihiko Yada1*
1 Division of Integrative Physiology, Department of Physiology, Jichi Medical University, Shimotsuke, Japan
2 Molecular Toxicology Section, Center for Environmental Health Sciences, National Institute for Environmental Studies, Tsukuba, Japan
3 Division of Histology and Cell Biology, Department of Anatomy, Jichi Medical University, Shimotsuke, Japan
4 Laboratory of Neuropsychopharmacology, Graduate School of Environmental and Human Sciences, Meijo University, Nagoya, Japan
5 Department of Pathobiochemistry, Faculty of Pharmacy, Meijo University, Nagoya, Japan
Edited by:
Akira Yoshii, McGovern Institute for
Brain Research at Massachusetts
Institute of Technology, USA
Reviewed by:
Kohichi Tanaka, Tokyo Medical and
Dental University, Japan
Tiago Moreira, Karolinska University
Hospital, Sweden
*Correspondence:
Toshihiko Yada, Division of
Integrative Physiology, Department
of Physiology, Jichi Medical
University, Shimotsuke, Tochigi
329-0498, Japan
e-mail: tyada@jichi.ac.jp
†These authors have contributed
equally to this work.
We previously reported that the type 2 diabetic Goto–Kakizaki (GK) rats at young adult
ages (6–12 weeks) exhibited increased visceral fat mass and hyperleptinemia, due to
hyperphagia caused primarily by neuropeptide Y (NPY) overexpression in the hypothalamic
arcuate nucleus. Later, we found that GK rats continued to exhibit mesenteric fat
accumulation and hyperleptinemia at least until 26 weeks of age, while hyperphagia and
NPY overexpression ceased at 15 weeks of age. Therefore, we hypothesized that the
long-lasting fat accumulation and hyperleptinemia are due to unidentified brain dysfunction
other than NPY overexpression. In GK rats aged 26 weeks, glucose transporter-2 (GLUT2)
mRNA expression in ventromedial hypothalamus (VMH) was markedly reduced in parallel
with significant decreases in brain-derived neurotrophic factor (BDNF) mRNA level and
BDNF-expressing cell numbers in the VMH. Pharmacologic inhibition of glucose utilization
reduced BDNF mRNA expression in VMH in vivo and in vitro. The results suggested
that impaired glucose utilization caused the reduction of BDNF. On the other hand,
intracerebroventricular injection of BDNF for 6 days ameliorated hyperleptinemia in a
long-lasting manner concurrently with feeding suppression in GK rats. Restricted feeding
paired to BDNF-treated rats reduced plasma leptin level only transiently. BDNF treatment
also reduced mesenteric fat mass in GK rats. These results reveal a novel action mode
of BDNF to long-lastingly counteract visceral adiposity and hyperleptinemia in addition
to and independently of its anorexigenic action. These results suggest that visceral fat
accumulation and hyperleptinemia are at least partly due to the reduction of BDNF in VMH
primarily caused by impaired glucose utilization in GK rats. The BDNF supplementation
could provide an effective treatment of visceral obesity, hyperleptinemia and leptin
resistance in type 2 diabetes.
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INTRODUCTION
The Goto–Kakizaki (GK) rat was established as an animal model
for type 2 diabetes by selecting Wistar rats which exhibited glu-
cose intolerance (Goto et al., 1976) and has been widely used to
investigate the mechanisms of glucose intolerance and complica-
tions of hyperglycemia (Yagihashi et al., 1982; Picarel-Blanchot
et al., 1996; Moreira et al., 2007). It has been reported that glucose
intolerance in GK rats is mainly caused by reduced β-cell mass
and impaired glucose-induced insulin secretion in β-cell (Portha
et al., 1991). Glucose intolerance of GK rats is also thought
to be partly due to impaired insulin sensitivity (Farese et al.,
1994).
Our particular concern in this study is how impaired insulin
sensitivity develops and is sustained in GK rats. We previ-
ously reported that impaired insulin sensitivity and increased
visceral fat mass occurred in parallel in young adult (6–12
weeks) GK rats (Maekawa et al., 2006a). The result indicated a
possibility that the increased visceral fat mass induced impair-
ment of insulin sensitivity. In young adult (6–12 weeks), the
increased fat mass was initiated by hyperphagia which was
caused by enhanced neuropeptide Y (NPY) mRNA expression
and impaired intracellular signaling of leptin in the hypothala-
mic arcuate nucleus (ARC) (Maekawa et al., 2006a). In GK rats,
it has been also reported that insulin sensitivity is impaired not
only at young adults but at middle-aged adults (Ndisang and
Jadhav, 2009). Middle-aged GK rat in our colony (22–35 weeks)
exhibited hyperleptinemia and higher mesenteric fat weight,
while hyperphagia and overexpression of NPY mRNA in ARC
were no longer observed (Maekawa et al., 2006a). Therefore,
it is speculated that the long-lasting fat accumulation and
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hyperleptinemia at middle-age are due to decreased energy
expenditure.
In this study, we focused on the relationship of brain-derived
neurotrophic factor (BDNF) to fat accumulation and plasma
leptin level in GK rat at middle-aged adult. In addition to well-
defined role of BDNF in the regulation of development, sur-
vival, differentiation and synaptic plasticity in the nervous system
(Tapia-Arancibia et al., 2004), it is also implicated in feeding
behavior and energy balance (Noble et al., 2011; Rios, 2013).
Heterozygous BDNF mutant mice and brain-specific BDNF
knockout mice, in which the BDNF gene is selectively deleted
in the brain after birth, showed increased food intake and body
weight (Lyons et al., 1999; Kernie et al., 2000; Rios et al., 2001).
Intracerebroventricular (icv) BDNF injection markedly reduced
body weight in several obesity models by reducing appetite
(Pelleymounter et al., 1995) and increasing energy expenditure
(Nakagawa et al., 2000). In the hypothalamus, BDNF-expressing
neurons are mainly localized in ventromedial hypothalamic
nucleus (VMH) and paraventricular nucleus (PVN) (Noble et al.,
2011). Since BDNF knockout in medial basal hypothalamus
containing VMH induced hyperphagia and obesity, the BDNF
neurons in this region is thought to be critical for regulat-
ing energy metabolism (Unger et al., 2007). BDNF neurons of
VMH possibly project to the neurons expressing corticotrophin-
releasing hormone (CRH) in PVN, since the CRH neurons
express TrkB, a receptor for BDNF, and icv injection of BDNF
increases CRH mRNA (Toriya et al., 2010). BDNF injection
decreased respiratory quotient and increased rectal temperature,
and these effects were antagonized by simultaneous treatment
with α-helical CRH9–41, a CRH receptor antagonist (Toriya et al.,
2010). These results suggested that the projection of BDNF neu-
rons to CRH neurons in PVN plays a critical role in energy
expenditure.
It has been reported that the BDNF expression in hypothala-
mus is regulated by several factors, which include neurotransmit-
ters such as melanocortins (Nicholson et al., 2007; Vanevski and
Xu, 2013), metabolic factors such as leptin (Komori et al., 2006),
insulin and glucose (Unger et al., 2007), and environmental cues
such as stress and environmental enrichment (Cao et al., 2010). In
addition, BDNF level in hypothalamus is altered in obesity and/or
diabetes models such as db/db, agouti yellow (Xu et al., 2003) and
SF-1 knockout mice (Tran et al., 2003). These reports suggest that
metabolic changes in obesity and diabetes result in and/or result
from the reduction of BDNF expression.
Here, we found that BDNF expression is reduced specifi-
cally in VMH in GK rats at middle-age. We investigated the
mechanism underlying the reduction of BDNF in VMH and
examined whether BDNF supplementation induces lipolysis and
ameliorates visceral obesity.
MATERIALS AND METHODS
ANIMALS
The GK rats purchased from Japan SLC (Shizuoka, Japan) were
maintained by breeding in the Center for Experimental Medicine,
Jichi Medical University. Adult male or pregnant Wistar rats were
purchased from Japan SLC. The rats were housed under a con-
trolled temperature (26◦C) and photoperiod (12L:12D). The rats
received pellet-type food (CE-2, Japan CLEA, Tokyo, Japan) and
tap water ad-libitum. The animal protocols were approved by the
Jichi Medical School Institute of Animal Care and Use Committee
and were in accord with the Japanese Physiological Society’s
guidelines for animal care.
mRNA EXTRACTION FROM BRAIN TISSUES AND cDNA SYNTHESIS
A portion of hypothalamus in each rat was dissected using a brain
slicer. The coronal slice of 2-mm thickness covering the ante-
rior part of VMH to the posterior part of ARC was obtained.
The tissues of the VMH and ARC were dissected with inci-
sions, and homogenized with TRIzol (Invitrogen, Carlsbad, CA).
Total RNAs were extracted following the protocol indicated by
the manufacturer. DNase (1U/10μl RNA solution, Promega,
Madison, WI) was added and the mixtures were incubated
for 1 h at 37◦C. Following the inactivation of DNase by heat,
cDNA was synthesized from 2μg total RNA with SuperscriptII
Reverse Transcription Kit (Invitrogen) utilizing oligo(dT)20
primer.
MIXED CULTURE OF CELLS FROM THE MEDIOBASAL HYPOTHALAMUS
AND mRNA EXTRACTION
The mediobasal hypothalamic tissue was isolated from the brain
of 6-day-old pups of Wistar rats, followed by dissociation of neu-
rons according to the procedures reported previously (Kohno
et al., 2007) with slight modification. Briefly, brain slices in
1mm-thickness were prepared, from which the tissues con-
taining the VMH and ARC were obtained. The 5–6 dissected
tissues were mixed and washed with 10mM HEPES-buffered
Krebs-Ringer bicarbonate buffer (HKRB) [(in mM): NaCl 129,
NaHCO3 5.0, KCl 4.7, KH2PO4 1.2, CaCl2 2.0, MgSO4 1.2
and HEPES 10 at pH 7.4] containing 10mM glucose. Then
they were incubated in HKRB supplemented with 20 units/ml
papain (Sigma-Aldrich, St. Louis, MO), 0.015mg/ml DNase, and
0.75mg/ml BSA for 12min at 36◦C in a shaking water bath,
followed by graded trituration. The cell suspension was incu-
bated on ice for 5min and a supernatant was centrifuged at
500 rpm for 5min. The pellet was resuspended in the culture
medium containing 50%minimal essential medium, 25%Hank’s
balanced salt solution, 25% horse serum (#12360-038, #24020-
117, #16050-122, Gibco BRL) and 10mM glucose. The cells
were distributed onto 96-well plates and short-term cultured.
Each well-contained ∼20% of cells removed from the brain of
a pup. Three h after the treatment with 2-deoxy-d-glucose (2-
DG) at various dosages, total RNA was extracted and cDNA was
synthesized.
mRNA MEASUREMENTS BY FLUORESCENCE REAL-TIME RT-PCR
Quantification of mRNAs was carried out using ABI PRISM
®7900-HT system (Applied Biosystems, Foster City, CA). The
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) level was
measured as an internal control. PCR primer sets for amplifica-
tion and TaqMan®probes with carboxyfluorescein in 5′end and
carboxytetramethyl-rhodamine in 3′end were purchased from
Sigma Genosys (Hokkaido, Japan) (Table A1). To detect GLUT8,
SybrGreen PCR was performed. Dividing each mRNA level by
the GAPDH level resulted in a normalized mRNA value. The
Frontiers in Synaptic Neuroscience www.frontiersin.org October 2013 | Volume 5 | Article 7 | 2
Maekawa et al. BDNF in diabetic Goto–Kakizaki rats
fluorescence real-time PCR was performed by the method as
described previously (Maekawa et al., 2006a). Dividing each
mRNA level by the GAPDH level resulted in a normalized mRNA
value.
Icv CANNULAE IMPLANTATION
Rats were anesthetized with Avertin (a mixture of 2,2,2-
tribromoethanol (T4840-2, Sigma-Aldrich) and Tert-amyl alco-
hol (24,048-6, Sigma-Aldrich), 200mg/kg, intraperitoneal). In
a stereotaxic frame, a 23-gauged stainless steel guide can-
nula was inserted into the brain with the tip in the third
cerebral ventricle, and secured to the skull with screws and
cement. The cannula tip was located at 0.9mm caudal to the
bregma and 7.0mm below the skull. After surgery, rats were
allowed to recuperate for 7 days. Handling of the operated
animals was performed for 10min everyday. For injecting sub-
stances, the internal cannula was inserted into the guide can-
nula and injection was executed for 1min under free-moving
conditions.
IMMUNOHISTOCHEMISTRY
A chicken anti-human BDNF polyclonal antibody (1:100, G1641,
Promega), a sheep anti-α-MSH antibody (1:30,000, AB5087,
Chemicon, Temecula, CA), a biotinylated rabbit anti-chicken
IgY (1:300, G2891, Promega), a biotinylated rabbit anti-sheep
IgG (1:300, BA-6000, Vector Laboratories, Burlingame, CA)
were used. Rats were intracerebroventricularly treated with 10μl
colchicine (100μg/10μl in distilled water). Forty-eight h after
injection, rats were perfused transcardially with 100ml of 2%
paraformaldehyde in 50mM phosphate buffer (PB), pH 7.5,
followed by 50ml of 50mM phosphate-buffered saline under
deep urethane anesthesia. Brains were removed, postfixed by the
same fixative for 2 h, cryoprotected with 30% sucrose in 50mM
PB for 2–3 days at 4◦C, sectioned coronally at 40-μm thick-
ness with a freezing microtome. The sections collected at every
160-μm interval were used. The localization of the target pro-
teins was determined as described previously (Maekawa et al.,
2006b).
Icv BDNF INJECTION, PLASMA HORMONE AND METABOLITES LEVELS
Wistar and GK rats were intracerebroventricularly injected with
BDNF (15μg/5μl saline/head) or vehicle once a day for 6
days. Plasma samples were obtained at the day before injection,
the 6th, 10th, 21st day after injection. Blood was withdrawn
from tail vein under unanesthetized condition. Glucose level was
determined by a conventional blood glucose-measuring device
(Glucocard, Arkray, Kyoto, Japan). Intraperitoneal glucose toler-
ance test (IpGTT) was performed under overnight fasting condi-
tions. Glucose (1 g/kg body weight) was injected and then blood
samplings from the tail vein were performed up to 3 h. For hor-
monal assay, plasma was immediately separated. Plasma leptin
and insulin concentrations were measured using ELISA kits for
leptin and insulin, respectively (#200728 and #200718, Morinaga
Institute of Biological Science, Yokohama, Japan). Plasma non-
esterified free fatty acid (NEFA) concentration was measured
using an assay kit for NEFA (#279-75401 NEFA C-test Wako,
Osaka, Japan).
MEASUREMENTS OF FOOD INTAKE AND BODY WEIGHT COMBINED
WITH PAIR-FEEDING
Food intake over 24 h was calculated by weighing the remain-
ing food pellets and body weight was measured between 11:00
and 12:00 h every day. For pair-feeding experiment, the amount
of food consumed by the BDNF-treated group over the course
of 24 h was measured at 11:00 h, and a corresponding amount of
pellets was given to the pair-fed group over a 24-h period.
MEASUREMENT OF FAT MASSES
At the completion of each experiment, interscapular, epididy-
mal, mesenteric, and perirenal fat were dissected and weighed. Fat
masses were calculated as percentage of body weight.
DATA ANALYSES
All data are expressed as mean ± SEM. The number of ani-
mals used is indicated in the parenthesis. One-Way ANOVA with
Holm’s post-hoc test was used for Figures 3D, 4, 5A,B, 6, 7A,B,
Table 2. Two-Way ANOVA with Tukey’s post-hoc test was used for
Figures 1B, 8, and Table 1. Other data was analyzed by Student’s
t-test with Microsoft Excel 2008 for Mac (Microsoft, Redmond,
WA). All statistical analyses except Student’s t-test were per-
formed using R (The R Foundation for Statistical Computing,
Vienna, Austria). p < 0.05 was considered significant.
RESULTS
METABOLIC INDICES OF GK RATS AT 26 WEEKS OF AGE
Casual blood glucose level in GK rat was significantly higher than
that in Wistar rat at 11 weeks and it increased further at 26 weeks
(Figure A1A). Intraperitoneal glucose tolerance test in GK rats
revealed that glucose intolerance progressed at 24 weeks, com-
pared to 14 weeks of age (Figure A1B). Mesenteric and perirenal
fat weights were larger in GK rats than in Wistar rats at 11 and 26
weeks of age (Table 1).
REDUCED BDNF EXPRESSION IN VMH OF GK RATS AT 26 WEEKS OF AGE
By comparison between Wistar and GK rats at 11 and 26 weeks
of age, BDNF mRNA level examined by real-time RT-PCR was
found to be reduced in VMH of GK rat specifically at 26 weeks of
age (Figure 1A, p < 0.05). Furthermore, immunohistochemistry
revealed marked reduction in the number of BDNF expressing
neurons selectively in VMH but not in PVN and nucleus trac-
tus solitarius (NTS) of GK rat at 26 weeks of age (Figures 1B–J,
p < 0.05 in B).
MECHANISM UNDERLYING THE REDUCED BDNF EXPRESSION IN VMH
OF GK RATS
α-MSH, melanocortin-4 receptor (MC4R), insulin, leptin and
glucose have been reported to affect BDNF expression. Hence, we
examined possible involvement of these factors in reduction of
BDNF expression in GK rat. Based on the previous report show-
ing a link between BDNF and α-MSH (Xu et al., 2003; Nicholson
et al., 2007), we examined a possible alteration of melanocortin
system in GK rats. By immunohistochemistry, localization of
α-MSH-immunoreactive neurons in the ARC of GK rats was
identical to that in control Wistar rats (Figures 2A,B). The cell
numbers of α-MSH-immunoreactive neurons in the ARC were
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Table 1 | Interscapular, epididymal, mesenteric and perirenal fat weights (% body weight) in control Wistar and diabetic GK rats at 11 and 26
weeks of age.
Age Strain No. Weight of fat pad (% BW)
Interscapular Epididymal Mesenteric Perirenal
11 weeks Wistar 6 0.09 ± 0.01 1.47 ± 0.08 0.63 ± 0.05 0.93 ± 0.04
GK 5 0.21 ± 0.02* 1.04 ± 0.05* 1.08 ± 0.04* 1.78 ± 0.11*
26 weeks Wistar 5 0.08 ± 0.02 1.52 ± 0.11 0.89 ± 0.05 1.55 ± 0.14
GK 6 0.12 ± 0.01 1.16 ± 0.07* 1.27 ± 0.12* 1.97 ± 0.11*
*p< 0.05 vs Control Wistar rats (Two-Way ANOVA with Tukey’s post-hoc test).
not different between GK and Wistar rats (Figure 2C). Similarly,
no difference in MC4R mRNA expression was found in the ARC
and VMH in GK rats (Figure 2D).
Next, the possible association of insulin and/or leptin with
BDNF reduction was examined. We tested whether the sup-
plementation of insulin would rescue BDNF reduction in GK
rats. GK rats were treated with intraperitoneal administra-
tion of insulin (1U/kg body weight) twice a day for 3 days,
which failed to restore the BDNF mRNA levels in the VMH
(Figure 2E). To examine the acute effect of insulin to increase
BDNF mRNA level in the VMH, single icv injection of insulin
(10mU/10μl saline) to Wistar rats was performed. However, it
did not increase the BDNF mRNA expression (Figure 2F). Icv
administration of leptin (5μg, twice a day for 3 days) in Wistar
rats under fasting condition failed to alter BDNF mRNA level
(Figure 2G).
Since transcription of BDNF in the VMH has been reported
to be regulated by glucose (Unger et al., 2007), we examined
the mRNA expression of genes related to the glucose utilization
in the VMH of GK rats using real-time RT-PCR. There was no
difference in GLUT4, GLUT8 and glucokinase mRNA expres-
sions between Wistar and GK rats (Figure 3A). In contrast, the
GLUT2 mRNA level was significantly reduced at 26 weeks com-
pared to 11 weeks of age (Figure 3B). To test the possibility that
reduction of glucose utilization affects BDNF mRNA level in the
VMH, 2-DG (5 mg/10μl saline), an inhibitor of glycolysis, was
administered icv to Wistar rats. 2-DG markedly reduced BDNF
mRNA level in the VMH as well as in hippocampus at 2 h after
treatment (Figure 3C). In a parallel in vitro experiment, bath
application of 2-DG to primary cultured neurons of medial basal
hypothalamus including the VMH dose-dependently reduced
BDNF mRNA expression (Figure 3D). These results indicate that
lowered glucose utilization in the VMH directly reduces BDNF
mRNA expression.
EFFECT OF BDNF TREATMENT ON PLASMA LEPTIN LEVEL AND FAT
MASS IN GK RATS
The effect of daily treatment with BDNF (15μg/5μl saline/head)
for 6 days on plasma leptin level and fat mass was examined
in Wistar and GK rats at 26 weeks. Plasma leptin level in GK
rats (GK-Vehicle group and GK-BDNF group) was significantly
higher than that inWistar rat before treatment (Day 0) (Figure 4),
confirming our previous report (Maekawa et al., 2006a). GK
rats subjected to treatment with saline revealed higher plasma
leptin level during experiment (GK-Vehicle group, Figure 4).
By contrast, the treatments with BDNF significantly decreased
plasma leptin level in both Wistar and GK rats (Wistar-BDNF
and GK-BDNF groups, respectively) at the timing of termination
of treatment (Day 6) and at 4 days after termination of treatment
(Day 10) (p < 0.01, Figure 4). Plasma leptin level at 15 days after
termination of treatment (Day 21) returned to the level before
treatment in GK rats of GK-BDNF group, while it was still low
in Wistar-BDNF group. At Day 21, weights of fat mass in all
groups were measured (Table 2). The weight of mesenteric fat in
BDNF-treated GK rats (GK-BDNF group) was significantly lower
than that in saline-treated GK rats (GK-Vehicle group, p < 0.05),
although it was higher than that in BDNF-treated Wistar rats.
EFFECT OF BDNF TREATMENT ON FOOD CONSUMPTION, BODY
WEIGHT, GLUCOSE TOLERANCE, AND NEFA LEVEL IN GK RATS
Daily food intake was significantly lowered both in Wistar-BDNF
and GK-BDNF groups during BDNF treatment (Figure 5A).
After termination of treatment, the food intake in Wistar-BDNF
and GK-BDNF groups rebounded to the same level as that in
GK-Vehicle group (Figure 5A). BDNF treatments also reduced
body weights in the rats of Wistar-BDNF and GK-BDNF groups
(Figure 5B). After termination of treatment, the body weight of
the BDNF-treated groups rebounded to the level close to that
before BDNF treatment (Figure 5B). Although the blood glucose
level in GK-BDNF level did not change during BDNF treatment,
after termination of treatment it became lower than that in GK-
Vehicle group, demonstrating the late-onset effect of BDNF on
glucose control (Figure 6). To investigate the mechanism how
BDNF lowered the casual glucose level in GK-BDNF group, we
performed IpGTT and measured glucose and insulin levels dur-
ing IpGTT (Figure 7). Blood glucose levels during IpGTT in
GK-Vehicle and GK-BDNF groups were markedly higher than
that in Wistar-BDNF groups at Day 0 (before treatment), Day 7
(immediately after termination of treatment), and Day 11 (after
termination of treatment) (Figure 7A). Blood glucose level dur-
ing IpGTT at Day 7 tended to increase, rather than decrease,
in GK-BDNF group. The higher glucose level at Day 7 in GK-
BDNF group is probably due to the lowered insulin level at
Day 7 (Figure 7B). These results taken together suggest that
BDNF treatments lowered casual blood glucose level by changing
insulin sensitivity but not by improving insulin secretion in GK
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FIGURE 1 | Expressions of BDNF mRNA and BDNF-immunoreactive cells
in Wistar and GK rats at 11 and 26 weeks of age. (A) BDNF mRNA levels
in VMH of Wistar and GK rats. Significant reduction of BDNF mRNA level
was found in GK rats at 26 weeks of age (∗p < 0.05, Student’s t-test). (B) At
26 weeks, significant reduction of the number of BDNF-immunoreactive
neurons was found in VMH, but not PVN and NTS, of GK rats (∗p < 0.05,
Two-Way ANOVA with Tukey’s post-hoc test). This reduction in VMH was not
different at 11 weeks. (C–J) Representative images of BDNF-immunoreactive
neurons in Wistar rats (C,E,G,I) and GK rats (D,F,H,J) at 26 weeks of age.
Broken lines in each image indicate the outline of PVN (C,D) and VMH (E,F).
No apparent difference was found in the PVN (C,D) and NTS (G,H). By
contrast, the number of BDNF-immunoreactive neurons in the VMH of GK
rats (F) was fewer than that of Wistar rats (E). At higher magnification, the
difference between Wistar (I) and GK (J) rats was obvious. III; the third
ventricle, IV; the fourth ventricle, cc; central canal. Scale bar = 500μm (C–H)
or 100μm (I and J).
rats. To examine whether exogenous BDNF treatment changes
plasma NEFA level in GK rats, we measured plasma NEFA level
in fed and 12h-fasted conditions. In GK-Vehicle group, plasma
NEFA level was higher in fasted condition at all time points
measured (Figure 8). In GK-BDNF and Wistar-BNDF groups,
plasma NEFA level was significantly increased both in fed and
fasted conditions at Day 6(fed)/7(fasted) and returned to pre-
treatment level at Day 10 (fed)/11(fasted) (Figure 8), indicating
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FIGURE 2 | Lack of alterations of melanocortines and effects of insulin
and leptin on BDNF mRNA expression in GK rats. (A,B) Representative
images of α-MSH-immunoreactive neurons in ARC of Wistar (A) and GK (B)
rats. III; the third ventricle, Scale bar = 500μm. (C) Numbers of
α-MSH-immunoreactive neurons in Wistar and GK rats. (D) MC4R mRNA
expressions in ARC and VMH were not different between Wistar and GK
rats. (E) Repeated intraperitoneal injection of insulin (1U/kg body weight,
twice a day for 3 days) in GK rats did not alter BDNF mRNA level in VMH.
(F) Single icv injection of insulin (10mU) in Wistar rats did not alter BDNF
mRNA levels in VMH. (G) Repeated icv injection of leptin (5μg, twice a day
for 3 days) to the fasting Wistar rats had no significant effect on BDNF
mRNA levels in VMH of Wistar rats.
the possibility that BDNF not only works as a feeding suppressant
but also increases lipolysis in GK rats.
COMPARISON OF PLASMA LEPTIN LEVELS BETWEEN GK-BDNF AND
GK-VEHICLE PAIR-FED GROUPS
We examined plasma leptin levels in GK-BDNF and GK-
Vehicle pair-fed groups (Figure 9). In GK-Vehicle pair-fed group,
GK rats were treated with saline and the amount of food
supplied was controlled to the same level as consumed by
GK-BDNF group. In GK-BDNF group, at Day 6 and 10
plasma leptin levels were markedly reduced (Figure 9). In GK-
Vehicle pair-fed group, plasma leptin level was lowered to
the same level as in GK-BDNF group at Day 6. However,
at Day 10 it increased to a level significantly higher than
that in GK-BDNF group, indicating that exogenous BDNF
counteracted visceral adiposity and hyperleptinemia via two
modes of action: in acute phase via anorexigenic action
and in late long-lasting phase via food intake-independent
mechanisms.
DISCUSSION
In this study, we found that middle-aged GK rats show abdom-
inal fat accumulation and hyperleptinemia, reduction in BDNF
mRNA expression and protein levels specifically in VMH, and
reduction in GLUT2 mRNA in VMH. Pharmacological block-
ade of glucose utilization in vivo and in vitro reduced BDNF
expression in VMH, suggesting that glucose availability posi-
tively regulates BDNF expression in VMH. In rescue experiment,
BDNF supplementation for 6 days ameliorated hyperleptinemia
and higher adiposity in a long-lastingmanner. These results reveal
that reduction of BDNF expression due to decreased GLUT2
expression and glucose utilization in VMH is linked to visceral
fat accumulation and hyperleptimemia in GK rats.
FAT ACCUMULATION AND GLUCOSE INTOLERANCE IN MIDDLE-AGED
GK RATS
It has been reported that glucose intolerance in human type 2 dia-
betes progresses with age (Gong and Muzumdar, 2012). A major
cause for this progression is insulin resistance due to genetic
and/or environmental factors. Especially, visceral fat accumula-
tion is of particular concern as a causal factor to induce insulin
resistance (Pouliot et al., 1992). Our breeding colony of GK rats
displayed these characteristic features common for the type 2
diabetes. First, hyperglycemia and glucose intolerance progressed
markedly at 24 weeks of age compared to 14 weeks (Figure A1).
Second, the visceral adiposity in mesenteric and perirenal fat pads
in GK rats was greater at 26 weeks of age than at 11 weeks. Third,
progression of hyperglycemia paralleled with progression of adi-
posity. These findings suggested that higher visceral adiposity is
related to the progression of glucose intolerance and that GK
rat is a suitable animal model to study interaction of glucose
intolerance and visceral adiposity in type 2 diabetes.
REDUCTION OF BDNF EXPRESSION IN VMH OF GK RATS AT MIDDLE
AGE
BDNF in the brain plays a critical role in regulating feeding
and metabolism. The BDNF neurons expressed in VMH and
PVN have been reported to contribute to the regulation of feed-
ing and metabolism (Noble et al., 2011). We found that the
GK rats aged 26 weeks display reduction of the BDNF mRNA
and protein in the VMH in parallel with progression of higher
adiposity. Regarding regulation of BDNF, it has been reported
that BDNF mRNA expression is modulated by the melanocor-
tine receptor 4 (MC4R) and downstream pathway (Xu et al.,
2003; Nicholson et al., 2007). Therefore, we examined a possi-
ble alteration of the α-MSH-MC4R system as a cause of BDNF
reduction in GK rats. However, neither the number of α-MSH-
immunoreactive neurons nor the MC4RmRNA levels in the ARC
and VMH were altered in GK rats at 26 weeks of age. We also
examined whether insulin and/or leptin influence BDNF expres-
sion in VMH. We could not find convincing evidence that insulin
and leptin regulate BDNF mRNA level in GK and Wistar rats.
We found that the GLUT2 mRNA level in VMH was sig-
nificantly reduced in GK rats. Previous studies in GK rats
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C D
FIGURE 3 | Reduction of GLUT2 paralleled with reduction of BDNF
expression in GK rats. (A) GLUT4, GLUT8 and gluokinase mRNA
expressions in VMH were unchanged in GK rats at 26 weeks. (B) GLUT2
mRNA expression in VMH was significantly reduced in GK rats at 26 weeks,
but not at 11 weeks (∗p < 0.05, Student’s t-test). (C) Effects of icv 2-DG
injection on BDNF mRNA levels in VMH were determined at 2 h after icv
injection of 2-DG (5mg/10μl) or saline (Sal). BDNF mRNA expression in VMH
and hippocampus (Hp) was significantly reduced by 2-DG (∗p < 0.05,
Student’s t-test). (D) Treatment with 2-DG for 3 h dose-dependently
suppressed BDNF mRNA level in cultured mediobasal hypothalamic cells.
The effects of 12 and 16mM 2-DG were significant (∗p < 0.05, One-Way
ANOVA with Holm’s post-hoc test).
FIGURE 4 | Effect of icv BDNF treatment daily for 6 days on plasma
leptin levels in GK rats. Plasma leptin levels at 0, 6th, 10th, 21st days after
beginning of BDNF or vehicle injections. BDNF treatment significantly
reduced plasma leptin level in GK rats. ∗p < 0.05 vs. other groups
(One-Way ANOVA with Holm’s post-hoc test).
reported reductions of GLUT1 in the retina (Fernandes et al.,
2004), GLUT2 in the pancreatic islets (Ohneda et al., 1993) and
GLUT4 in the heart (Desrois et al., 2004). Glucose uptake in
the skeletal muscle was also reported to be impaired in GK rats
(Krook et al., 1997). As a causal factor of GLUT reduction, it
has been implicated that over-activation of hexosamine pathway
by hyperglycemia decreases the expression level of GLUT2 in
the pancreatic β-cells, eventually leading to the inhibition of
glucose-stimulated insulin secretion and induction of apopto-
sis in β-cells (Yoshikawa et al., 2002). The down-regulation of
GLUT2 is expected to suppress the glucose uptake and utilization
in a specific subset of neurons presumably including BDNF-
expressing neurons, which could suppress BDNF mRNA in the
VMH of GK rats. In support of this speculation, icv injection
of 2-DG in Wistar rats, a procedure used to impair the glucose
utilization and mimics the impairment in GK rats, significantly
decreased BDNFmRNA level in the VMH. Furthermore, the bath
application of 2-DG to the cells isolated from the medial basal
hypothalamus including VMH, significantly decreased BDNF
mRNA level. Our in vitro results demonstrate that BDNF expres-
sion in VMH is directly regulated by glucose availability within
BDNF neurons. Oomura et al. originally found subpopulations
of neurons in the VMH that respond to hyperglycemic or hypo-
glycemic condition (Oomura et al., 1969; Mizuno and Oomura,
1984; Nakano et al., 1986). Experimental cytosolic Ca2+ imag-
ing combined with single-cell RT-PCR showed that up to 60% of
glucose-sensing neurons in the VMH express glucokinase mRNA
(Kang et al., 2004). It could be speculated that BDNF neurons
in VMH have machinery to sense extracellular glucose level and
change BDNF mRNA expression. GLUT2 and glucokinase are
the candidate machineries. It has been reported that GLUT2
is expressed in a specific subset of VMH neurons in the brain
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Table 2 | Effect of BDNF on interscapular, epidiymal, mesenteric and perirenal fat weights (% body weight) in GK rats.
Strain Treatment No. Weight of Fat pad (% BW)
Interscapular Epididymal Mesenteric Perirenal
GK Vehicle 6 0.15 ± 0.01 1.02 ± 0.11 1.14 ± 0.08 1.18 ± 0.14
GK BDNF 5 0.17 ± 0.02 0.80 ± 0.07 0.80 ± 0.09* 0.97 ± 0.17
Wistar BDNF 4 0.05 ± 0.01* 0.99 ± 0.08 0.55 ± 0.06* 0.56 ± 0.07*
Fat weights of saline-treated GK rats (GK-Vehicle group, 5µl saline/head, n = 6), BDNF-treated GK rats (GK-BDNF group, 15µg/5µl saline/head, n = 5) and BDNF-
treated Wistar rats (Wistar-BDNF group, 15µg/5µl saline/head, n = 4) at Day 21 after the beginning of injections were examined. Interscapular: *p < 0.05 vs. other
groups, Mesenteric: *p < 0.05 vs. GK-Vehicle, Perirenal: *p < 0.05 vs. GK-Vehicle, One-Way ANOVA with Holm’s post-hoc test.
A
B
FIGURE 5 | Effect of BDNF treatment on food intake and body weight
in GK rats. (A) Daily food intake was examined before and after BDNF
treatment (15μg/5μl saline/head) for 6 days. BDNF treatment significantly
reduced daily food intake during period of treatment in both GK-BDNF and
Wistar-BDNF groups. ∗p < 0.05 vs. other groups (One-Way ANOVA with
Holm’s post-hoc test). (B) Body weight was examined before and after
treatment of BDNF for 6 days. BDNF treatment significantly reduced body
weight in both GK-BDNF and Wistar-BDNF groups. ∗p < 0.05 vs. other
groups (One-Way ANOVA with Holm’s post-hoc test).
(Arluison et al., 2004) and certain population of GLUT2-
expressing neurons in VMH have a property to respond to
change of extracellular glucose concentration (Kang et al., 2004).
Considering that both GLUT2-expressing and BDNF-expressing
neurons are able to respond to glucose, the two populations could
be overlapped. This hypothesis should be examined by either
double immunostaining or in situ hybridization of BDNF and
GLUT2 in future study. Taken together, our finding demonstrates
the possibility that the BDNF mRNA expression in the VMH
is controlled by glucose metabolism in which glucokinase and
GLUT2 might play a role.
FIGURE 6 | Effect of BDNF treatment on casual blood glucose level in
GK rats. Although BDNF did not alter blood glucose level during treatment,
significant reduction of blood glucose level was observed after termination
of BDNF treatment in GK-BDNF group (∗p < 0.05 vs. other groups,
One-Way ANOVA with Holm’s post-hoc test).
In middle-aged GK rats with reduced level of BDNF in VMH,
hyperphagia was not found as shown in previous study (Maekawa
et al., 2006a). On the other hand, it has been reported that the
reduced level of BDNF in medial basal hypothalamus by con-
ditional BDNF gene knockout causes hyperphagia (Unger et al.,
2007). What causes the difference between these phenotypes? It
has been reported that the BDNF neurons in VMH regulate var-
ious physiological functions such as feeding, energy expenditure,
and blood glucose control (Noble et al., 2011). It could be spec-
ulated that each function is assigned to a specific subgroup of
BDNF-expressing neurons in VMH. Since the BDNF-expressing
neurons at the level up to 30% of that in Wistar rats persisted
in middle-aged GK rats, such subgroup of BDNF neurons might
play a role in preventing hyperphagia whereas the subgroupmight
take no part in the regulation of lipolysis. This possibility should
be validated in future study.
CENTRAL BDNF SUPPLEMENTATION AMELIORATED HIGHER
ADIPOSITY IN GK RATS
It has been reported that lesioning the VMH induces not only
hyperphagia but also amarked visceral fat accumulation inWistar
(Bray and Nishizawa, 1978) and GK rats (Yoshida et al., 1996),
and that the loss of neurons in the VMH induces dysfunction of
lipolysis. The neurons in VMH are known to project to various
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A B
FIGURE 7 | Intraperitoneal glucose tolerance test before and after
BDNF treatment in GK rats. BDNF treatment did not attenuate glucose
intolerance (A) and impaired insulin release (B) during glucose tolerance
test in GK rats throughout experiment. (A) ∗p < 0.05 vs. GK-Vehicle and
GK-BDNF (One-Way ANOVA with Holm’s post-hoc test). (B) ∗p < 0.05 vs.
GK-Vehicle in Day 0 (30min), Day 7 (15min), ∗p < 0.05 vs. GK-BDNF in Day 7
(15min, 30min) and 11 (15min), One-Way ANOVAwith Holm’s post-hoc test.
brain areas. In our previous report using Wistar rats (Maekawa
et al., 2006b), only 19% of BDNF neurons of VMH project to
midbrain central gray, a region known to be innervated by VMH
neurons. PVN is one of possible candidates for primary synap-
tic transmission of VMH BDNF neurons. Our previous report
suggested that TrkB receptor, a neurotrophin receptor specific
for BDNF, is expressed in CRH neurons of PVN and icv BDNF
injection increases the CRH mRNA in PVN (Toriya et al., 2010).
Although there is no direct evidence that BDNF neurons of VMH
are connected to CRH neurons in PVN, these results obtained by
physiological experiments indirectly support the possibility that
the VMH BDNF neurons project to CRH neurons in PVN. It
has been demonstrated that CRH neuron in PVN regulates both
sympathetic tone and hypothalamic-pituitary-adrenal axis and
that CRH neurons positively control lypolysis (Yada et al., 2012).
Our previous report demonstrated that lypolytic effect of BDNF
was countracted by simultaneous treatment with CRH receptor
antagonist, suggesting that the lypolytic effect of BDNF is medi-
ated by CRH release from CRH neurons in PVN (Toriya et al.,
FIGURE 8 | Effect of BDNF on NEFA levels before and after treatment
to GK rats in fed and fasted conditions. Plasma NEFA levels in fed and
12 h-fasted conditions at time points before treatment (Day –1/0),
immediately after termination of treatment (Day 6/7), and 4/5 days after
termination of treatment (Day 10/11) were measured. Plasma NEFA level
was higher in fasted condition at all time points measured in all groups
[Pre(Day –1/0), p < 0.05 vs. fed conditions, Two-Way ANOVA with Tukey’s
post-hoc test]. At time point immediately after termination of treatment
(Day 6/7), plasma NEFA levels in Wistar-BDNF and GK-BDNF groups were
increased both at fed and fasting conditions. Especially, plasma NEFA levels
in Wistar-BDNF and GK-BDNF groups at fasting condition were significantly
higher than those in GK-Vehicle group at fasting condition (∗p < 0.05,
Two-Way ANOVA with Tukey’s post-hoc test). Such tendency continued to
Day 10/11 but there was no significant difference at this time point.
2010). Thus, our present and previous results taken together sug-
gest a possibility that the reduction of BDNF in VMH impairs
lipolysis via reducing CRH release in GK rats. Other than CRH
release, TrkB and CRH receptor in hypothalamus including PVN
might be changed concomitantly with the change in CRH release
in GK rats. Such possibilities should also be taken into account
when elucidating the etiology of visceral fat accumulation in GK
rats.
BDNF has been reported to regulate the binding of cAMP
response-element binding protein (CREB) and coactivator pro-
teins to CRH promoter and thereby positively control transcrip-
tion of CRH (Jeanneteau et al., 2012). Activation of phospholipase
Cγ might mediate the BDNF-TrkB signaling by triggering Ca2+
increase, activating adenylate cyclase and subsequently increasing
cAMP concentration (Ji et al., 2005). On the other hand, BNDF
works not only as a neurotransmitter but as a regulator of synap-
tic structural plasticity (Yoshii and Constantine-Paton, 2010).
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FIGURE 9 | Comparison of plasma leptin levels between GK-BDNF and
GK-Vehicle pair-fed groups. In both groups, plasma leptin levels at Day 6
were decreased after BDNF and pair-fed treatments. At Day 10, plasma leptin
level in GK-BDNF group remained low while that in GK-Vehicle pair-fed group
was significantly elevated (∗p < 0.05, Student’s t-test).
The regulation includes spine formation by altered localization
of postsynaptic proteins such as PSD-95 (Yoshii et al., 2003).
Regulation of synaptic plasticity by BDNF, a process thought to be
requisite for learning both at juvenile and adult ages (Poo, 2001;
Lu et al., 2008; Suzuki et al., 2012), might also be related to the
control of feeding and energy metabolism.
FUTURE PERSPECTIVE
Themolecularmechanisms connecting lower glucosemetabolism
to BDNF reduction remained unclear in this study. One of key
proteins that link glucose metabolism to BDNF expression is
SIRT1, a metabolic sensor by working as a NAD+-dependent
deacetylase. It has been reported that SIRT1 controls BDNF
expression by deacetylating MeCP2 (Zocchi and Sassone-Corsi,
2012), by enhancing CREB-TORC1 transcriptional activity
(Jeong et al., 2011), and by suppressing expression of specific
microRNA which binds to BDNF mRNA (Gao et al., 2010).
Another possible protein to link glucose metabolism to BDNF
expression is neuron-restrictive silencer factor (NRSF). The
NRSF, a transcriptional repressor, has been reported to recruit the
NADH-binding co-repressor CtBP to BDNF promoter. Notably, it
has been also reported that glycolysis inhibition by 2-DG injection
reduces BDNF transcription by NRSF-CtBP-dependent change of
histone modification (Garriga-Canut et al., 2006). Involvements
of such proteins to BDNF reduction should be examined in future
study.
In this study, we found that BDNF treatments reduce fat mass
and lower casual blood glucose level by changing insulin sensitiv-
ity. However, BDNF could not restore the insulin secretion in GK
rats. Therefore, to improve the glycemic control in type-2 diabetes
more effectively, the simultaneous treatment with BDNF and the
drug having a function to alleviate impaired insulin secretion
might be required. Therapeutic potential of the combination of
BDNF with the drug enhancing insulin secretion against diabetes
should be investigated in future study.
CONCLUSION
In this study, we present the following scenario to explain how the
higher visceral adiposity continues in GK rats until middle-aged
adult. (1) The hyperglycemia and/or other diabetes-associated
factors suppress the GLUT2 expression to lower the glucose avail-
ability in VMH. (2) The reduction of glucose availability leads to
impair BDNF expression in VMH. (3) The reduced BDNF level
attenuates lypolysis and accelerates glucose intolerance. Further
studies are required to validate whether this scenario in GK rats
is more generally applicable to other diabetes and/or obesity
models.
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APPENDIX
A B
FIGURE A1 | Glycemic profiles of GK rats. (A) The blood glucose
level under fed conditions in Wistar and GK rats at the age of 11 and
26 weeks. The blood glucose level in GK rats was significantly higher
than that in Wistar rats at both 11 and 26 weeks (∗p < 0.05 and
∗∗p < 0.01, respectively, Student’s t-test). The difference was greater
at 26 weeks. (B) Profiles of IpGTT in GK rats at 14 and 24 weeks.
One g/kg body weight glucose (0.1 g/ml in distilled water) was
injected at 0min and blood glucose was measured at 0, 30, 60, and
120min after injection. The glucose intolerance was progressed in GK
rats at 24 weeks of age (∗∗p < 0.01, Student’s t-test).
Table A1 | Primer sequences used for real-time RT-PCR.
mRNA (Abbreviation) Genbank accession
number (amplicon)
Primers Probe (5′-FAM, 3′-TAMRA)
Brain-derived neurotrophic
factor (BDNF)
NM012513 (504-571) Fwd: CCATAAGGACGCGGACTTGTAC
Rvs: GAGGAGGCTCCAAAGGCACTT
CTTCCCGGGTGATGCTCAGCAGT
Melanocortin-4 receptor
(MC4R)
NM013099 (731-819) Fwd: TGGCGAGGCTTCACATTAAGA
Rvs: CAAGGTAATTGCGCCCTTCA
CACGGGTACCATCCGACAGGGTG
Glucose transporter-2
(GLUT2)
NM012879 (818-898) Fwd: GTCCAGAAAGCCCCAGATACC
Rvs: TGCCCCTTAGTCTTTTCAAGCT
TTGCCCTGACTTCCTCTTCCAAATTTAGGT
Glucose transporter-4
(GLUT4)
NM012751 (818-907) Fwd: CCCCCGATACCTCTACATCATC
Rvs: GCATCAGACACATCAGCCCAG
CTGCCCGAAAGAGTCTAAAGCGCCT
Glucose transporter-8
(GLUT8)
NM053494 (1049-1235) Fwd: TCATGGACAGAGCAGGGCG
Rvs: GCCAGCCAGGCCAGCCCCA
Not used
Glucokinase NM012565 (1330-1414) Fwd: CAAGCTGCACCCGAGCTT
Rvs: TGATTCGATGAAGGTGATTTCG
TCAGCCTGCGCACACTGGCG
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